Recursion Pharmaceuticals

RXRX50

$6.31arrow_drop_up3.10%$0.19

RXRX50

$6.31

arrow_drop_up3.10%$0.19

Performance History

Key Stats
Open	$6.16
Prev. Close	$6.12
EPS	-1.66
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	6.06	6.19
52 Week Range	4.97	15.74

Ratios







EPS	-1.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. (RXRX) is a biotechnology company focused on developing therapeutics using artificial intelligence and machine learning. The company is known for its innovative approach to drug discovery and has made significant strides in the field of precision medicine. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

The stock price history of Recursion Pharmaceuticals, Inc. (RXRX) has shown significant growth over the years. Since its initial public offering, the stock price has steadily risen, reflecting the company's strong performance and promising prospects. Investors have been bullish on the stock, with many seeing it as a potential game-changer in the healthcare industry.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Christopher C. Gibson Ph.D.
Headquarters: Salt Lake City
Employees: 550
Exchange: NASDAQ

add Recursion Pharmaceuticals to watchlist

Keep an eye on Recursion Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Recursion Pharmaceuticals (RXRX)?

Recursion Pharmaceuticals (RXRX) has a market capitalization of $1.67B. The average daily trading volume is 4.81M, indicating the stock's liquidity and investor engagement.

help

What is Recursion Pharmaceuticals's (RXRX) price per share?

The current price per share for Recursion Pharmaceuticals (RXRX) is $6.31. The stock has seen a price change of $0.19 recently, indicating a 3.1% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Recursion Pharmaceuticals (RXRX)?

For Recursion Pharmaceuticals (RXRX), the 52-week high is $15.74, which is 149.45% from the current price. The 52-week low is $4.97, the current price is 26.96% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Recursion Pharmaceuticals (RXRX) a growth stock?

Recursion Pharmaceuticals (RXRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 31 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Recursion Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Recursion Pharmaceuticals (RXRX) stock price performance year to date (YTD)?

As of the latest data, Recursion Pharmaceuticals (RXRX) has a year-to-date price change of -36.07%. Over the past month, the stock has experienced a price change of 0.32%. Over the last three months, the change has been -26.8%. Over the past six months, the figure is -39.15%.

help

Is Recursion Pharmaceuticals (RXRX) a profitable company?

Recursion Pharmaceuticals (RXRX) has a net income of -$328.07M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -697.39% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $44.58M, with a revenue growth rate of 12.33%, providing insight into the company's sales performance and growth. Operating income is noted at -$350.06M. Furthermore, the EBITDA is -$364.95M.